Cipla has launched its Synchrobreathe breath actuated inhaler in South Africa, the company announced. In 2015, Cipla had said that it expected to launch the inhaler by the end of that year.
Cipla Medpro CEO Paul Miller said, “Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South Africa. In addition, the inspiratory flow required to automatically trigger the inhaler mechanism is low, which makes it attractive to a large number of patients, such as very young or old patients with severe lung impairment. Synchrobreathe is a breath-actuated inhaler with a true built-in dose counter allowing patients to track doses, thereby encouraging patient compliance.”
Miller added, “As a leading pharmaceutical company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation. Cipla’s Research and Development team, which specializes in respiratory inhalers, has been developing the product over several years. The launch and availability of the Synchrobreathe inhaler is in line with the company’s commitment to bring innovative solutions to best fit the needs of both physicians and patients, thereby advancing healthcare for all.”
Read the Cipla press release.
